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Summary
Objective: To evaluate vancomycin utilization according to the adapted criteria of
the Centers for Disease Control and Prevention (CDC) with a report of the effect of
education program on the utilization.
Method: We evaluated the utilization of vancomycin over a 3-month period pre- and
post-intervention using educational activity.
Results: In the pre-intervention period, of the 74 adult patients vancomycin was
prescribed for speciﬁc treatment in 66% (n = 49), empirical therapy in 26% (n = 19)
and as a prophylaxis in 8% (n = 6). Vancomycin utilization was considered appropriate
based on the CDC recommendations in 48 (65%) patients. Forty-seven (64%) patients
received an appropriate dose regimen based on weight, age and creatinine clear-
ance. Only 31% (n = 23) of patients had both peak and trough levels taken around
the third dose. In the post-intervention period, vancomycin was used as speciﬁc
therapy in 41% (n = 14) and empirically in 59% (n = 20). Compliance with guidelines
for empirical use of vancomycin improved from 21% in the pre-intervention phase to
85% after the intervention (P = .0001). In addition, compliance with vancomycin use
in speciﬁc therapy was 100% compared to 82%. Compliance rate with vancomycin
trough level monitoring increased from 35% in the pre-intervention period to 67.7%
in the post-intervention period (P = 0.0002).
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Conclusion: In conclusion, in addition to the utilization of CDC based criteria for van-
comycin, we had shown that patient’s chart review by a clinical pharmacists with a
feed back to the physicians when guidelines were not met coupled with and educa-
tional efforts are effective methods to decrease inappropriate vancomycin usage.
dulaziz University for Health Sciences. Published by Elsevier
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Materials and methods
Established in 1949, today DHC is a 390-bed
tertiary care facility with eighteen units (e.g.,
pediatrics, internal medicine, critical care, car-
diology, obstetrics, orthopedic, and surgical care)
and seven ambulatory care services. DHC is a facil-
Table 1 Situations in which the use of vancomycin
should be discouraged according to CDC recommen-
dations [1].
Routine surgical prophylaxis
Empiric therapy for febrile neutropenia unless initial
evidence suggests a Gram-positive infection and the
prevalence of infections caused by MRSA is high in
the institution
Treatment in response to a single blood culture
positive for coagulase-negative Staphylococcus, if
other blood cultures drawn in the same time frame
are negative (i.e. contamination of culture)
Continued empiric use when cultures are negative for
beta-lactam resistant Gram-positive organisms
Systemic or local prophylaxis of indwelling central or
peripheral intravascular catheters
Selective decontamination of the digestive tract
Eradication of MRSA colonization
Primary treatment of antibiotic-associated colitis
Routine prophylaxis for very low birth weight infant
Routine prophylaxis for patients on continuous
ambulatory peritoneal dialysis or hemodialysis
Treatment (chosen for dosing convenience) of© 2009 King Saud Bin Ab
Ltd. All rights reserved.
Introduction
Over the past couple decades; a high rate of antibi-
otic resistance among Gram-positive organisms
has become a serious concern among the med-
ical health professions [1,2]. Methicillin-resistant
Staphylococcus aureus (MRSA) and methicillin-
resistant Staphylococcus epidermidis (MRSE) are
major causes of hospital-acquired infections world-
wide, and are becoming increasingly difﬁcult to
combat because of emerging resistance to cur-
rent antimicrobials. MRSA was ﬁrst reported in the
United Kingdom in early 1961 [3], and was soon
recovered from other European countries, and later
from Japan, Australia, and the United States [4,5].
Furthermore, resistances among Gram-positive
organisms are seen in out patient setting as well
[6]. In the year 2004, the rate of MRSA among
United States hospitalized intensive care units
patients was approximately 60% due to the inap-
propriate use of antibiotics [7]. This increase in
methicillin-resistant organisms triggered the use
of glycopeptide antibiotics such as vancomycin for
patients with known or suspected MRSA or MRSE
infections. Inappropriate use of vancomycin may
not only increase cost but may also increase the
rates of resistant Gram-positive organisms espe-
cially vancomycin resistant enterococci (VRE) [8,9].
The rate of VRE has increased in recent years
thus raising great public health concerns. Con-
sequently, the Hospital Infection Control Practice
Advisory Committee at the Centers for Disease
Control and Prevention (CDC) published recom-
mendations for the prevention of the spread of
vancomycin resistance [1]. Based on these rec-
ommendations, vancomycin usage criterion was
developed at Dhahran Health Center (DHC) in the
late 1990s (Tables 1 and 2). These criteria were
communicated (verbally and written) to all medical
staff. It is important to note that the recommenda-
tions for prophylaxis of infective endocarditis had
been changed after the criteria were established
[10]. In our institution, Dhahran Health Center
(DHC), MRSA isolates represents 2% in 1999, 9.7%
in 2002 and 8% in 2003 based on ﬁrst isolate per
patient analysis [11].There are sparse data on the use of vancomycin
n this part of the world. The objective of this study
as to evaluate the appropriateness of vancomycin
se, according to the rules of the Hospital Infection
ontrol Practices Advisory Committee (HICPAC) [1].
e compared the effect of continuous education
nd active feedback on the practice of vancomycin
rescription. The other aims included the evalu-
tion of the proper dosage and therapeutic drug
onitoring.infections caused by beta-lactam susceptible
organisms in patients who have renal dysfunction
Use of vancomycin for topical application or irrigation
CDC: Centers for Disease Control and Prevention.
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Table 2 Appropriateness of vancomycin therapy at
SAMSOa.
Speciﬁc treatment
Treatment of serious infections caused by
beta-lactam-resistant Gram-positive
micro-organisms
Treatment of infections caused by
methicillin-resistant Staphylococcus aureus
(MRSA) and methicillin-resistant Staphylococcus
epidermidis (MRSE)
Treatment of infections caused by Gram-positive
micro-organisms in patients who have serious
allergies to beta-lactam antimicrobials
Oral vancomycin is appropriate when
antibiotic-associated colitis fails to respond to
metronidazole therapy or is severe and
potentially life-threatening.
Prophylaxis
Prophylaxis of bacterial endocarditis in
penicillin-allergic adults and children with
congenital heart disease, rheumatic or other
acquired valvular heart dysfunction, prosthetic
heart valves, surgically constructed systemic
pulmonary shunts or conduits, hypertrophic
cardiomyopathy, mitral valve prolapse with
valvular regurgitation and/or thickened leaﬂets,
or previous bacterial endocarditis, who undergo
certain GI, biliary tract, or genitourinary surgery
or instrumentation likely to cause transient
bacteremia and increase the risk of endocarditis
Surgical prophylaxis for major procedures involving
implantation of prosthetic materials or devices if
a high incidence of MRSA or MRSE is present in the
institution.
Empiric treatment
Empiric therapy for febrile neutropenia if initial
evidence suggests a Gram-positive infection and
the prevalence of infections caused by MRSA is
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a Adapted from the recommendations of the Centers for
Disease Control and Prevention [1].
ty of Saudi Aramco Medical Services Organization
SAMSO) which is part of the Saudi Arabian Oil Com-
any (Saudi Aramco) that services over 350,000
mployees and their dependents. SAMSO is one of
ew organizations in the region that is currently
ccredited by the Joint Commission International
ccreditation (JCIA).
Chart reviews were conducted to evaluate
ntravenous vancomycin use in DHC. All adult
atients who received vancomycin over a 3-
onth pre-intervention period were evaluated.
AMSO ‘‘Software Application ProgramTM’’ system
as used to identify all patients that utilized
ancomycin during the study period. Patients’
nformation was collected on pre-approved forms
P
S
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p143
hat included the following: demographic data,
dmission diagnosis, site of infection, history of
resent illness, allergies, concurrent antibiotics
nd other nephrotoxic drugs, vancomycin dosage,
oute of administration, duration of vancomycin,
ancomycin related adverse effects, cultures
nd sensitivity test results, vancomycin levels,
rine analysis, complete blood count and chem-
stry. Appropriate vancomycin dosing regimen
as based on weight, age and creatinine clear-
nce (normal renal function: 15—20mg/(kg dose)
very 12 h [30—45mg/(kg dose) for meningi-
is]; creatinine clearance (crcl) 40—60ml/min:
5—20mg/(kg dose) every 24 h; creatinine clear-
nce (crcl) 25—39ml/min: 15—20mg/(kg dose)
very 48 h; crcl < 25: initial loading dose of
5—20mg/kg, then determined by serum concen-
ration monitoring). Cockcroft and Gault equation
as utilized to calculate creatinine clearance
12]. A clinical pharmacist along with an Infec-
ious Disease consultant collected and reviewed
hese data and evaluated the appropriateness of
ancomycin use based on DHC usage criteria that
re derived from the CDC recommendations [1].
ach vancomycin course was classiﬁed as: empir-
cal therapy, speciﬁc treatment, or prophylactic.
escriptive statistics were utilized to evaluate the
esults, and continuous variables were reported as
ean± standard deviation.
We compared the compliance with vancomycin
se prior to our intervention (‘‘pre-intervention
ata’’) to the data after interventions (‘‘post-
ntervention data’’). For each time period, we
sed point prevalence surveys to collect data. The
ntervention began in 2008 and included review of
he patient’s chart and hospital data by clinical
harmacists. The pharmacist then contacted the
hysicians when guidelines were not met and they
iscussed alternative antimicrobial therapy. If van-
omycin use still continued, an infectious diseases
onsultation was then considered. In addition, edu-
ational blitzs including presentations, and e-mail
eminders, verbal communications and letters was
ent to educate health care workers about the
ppropriate use of vancomycin. A chi-square test
as used to compare the statistical difference
etween the pre- and post-intervention data.
esultsre-intervention data
eventy-four adult patients (46 males and 28
emales) were identiﬁed during the 3-month study
eriod wit a mean age (±S.D.) of 62.5± 19 years.
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Table 3 Distribution of vancomycin use by service.
Service Before intervention, no. (%) patient (N = 74) Post-intervention, no. (%) patient (N = 34)
Internal medicine 53 (71.6) 25 (73.5)
Critical care 9 (12.2) 5 (14.7)
Surgery 10 (13.5) 4 (11.8)
Oncology 2 (2.7) 0
Table 4 Summary of appropriateness of vancomycin utilization.
Indication Before intervention (n = 74) Post-intervention (n = 34) P value
Appropriate, n/N (%) Appropriate, n/N (%)
All indications 48/74 (65) 31/34 (91) 0.004
Speciﬁc treatment 40/49 (82) 14/14 (100) 0.56
e
l
f
t
a
1
T
I
t
a
4
4
t
p
t
r
tProphylaxis treatment 4/6 (67)
Empiric treatment 4/19 (21)
Table 3 shows the distribution of vancomycin use by
medical services. All patients received intravenous
vancomycin with a mean duration of 6.1± 6 days.
Vancomycin was prescribed for a speciﬁc treatment
in 66% (n = 49), empiric therapy in 26% (n = 19) and
as prophylaxis in 8% (n = 6). Vancomycin utilization
was considered appropriate based on the predeter-
mined usage criteria in 48 patients (65%).
Empirical therapy was the most common inap-
propriate indication (Table 4). The mean duration
of vancomycin speciﬁc, empiric and prophylaxis
treatment was 7.5, 2.5 and 1.5 days, respectively.
Furthermore, 47 patients (64%) received an appro-
priate dosing regimen based on weight, age and
creatinine clearance. Pretreatment cultures and
sensitivities were performed in 85% of the patients.
Post-intervention dataA point prevalence survey was done >6 months after
the start of the intervention. A total of 34 patients
were evaluated over a 3-month period. Vancomycin
was used as speciﬁc therapy in 41% (n = 14) and
(
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d
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Table 5 Peak and trough monitoringa.
Description Before
n/N (%)
Peak and trough not-monitored 25b (34
Peak and trough monitored 49 (66
Peak and trough around the 3rd dose 15 (31
Peak and/or trough not around the 3rd dose 34 (69
Peak and trough other than the 3rd dose 9 (27
Trough only 12 (35
Random level 13 (38
a Recommended therapeutic range: peak: 30—45mcg/ml; trough
b Did not require vancomycin monitoring since the medication w0 —
17/20 (85) 0.0001
mpirically in 59% (n = 20). Compliance with guide-
ines for empirical use of vancomycin improved
rom 21% in the pre-intervention phase to 85% after
he intervention (P = .0001). In addition, compli-
nce with vancomycin use in speciﬁc therapy was
00% compared to 82% (Table 4).
herapeutic vancomycin monitoring
n the pre-intervention period, baseline renal func-
ion assessment was done in 73 patients (98.6%)
nd vancomycin initial dose was adjusted in all
1 patients with baseline renal impairemnet. Only
9 patients had peak and/or trough (P&T) levels
aken in the study population (Table 5). Of the 49
atients, 43% and 49% of the P & T levels respec-
ively, were within the recommended therapeutic
ange. In addition, 81% of peak levels and 97% of
rough levels were taken at the appropriate time
peak level 1—2 h after infusion completed and
rough level within 30min prior to the subsequent
ose). Only three patients received other nephro-
oxic drugs (e.g. aminoglycosides) concurrently. No
intervention, After intervention,
n/N (%)
P value
) 0
) 31 (100)
) 2 (6.4)
) 0
) 0
) 21 (67.7) 0.0002
) 8 (25.8) 1.0
: 10—15mcg/ml.
as used for prophylaxis or was received for <3 doses.
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ajor adverse effects were reported during this
eriod secondary to vancomycin therapy.
The compliance rate with vancomycin ther-
peutic monitoring improved remarkably in the
ost-intervention period. The compliance rate with
rough level monitoring increased from 35% in
he pre-intervention period to 67.7% in the post-
ntervention period (P value = 0.0002) (Table 5).
iscussion
n hospitals where MRSA is the predominant S.
ureus, a high institutional use of empiric van-
omycin is expected. At our institution, out of all S
ureus, MRSA isolates represents 2% in 1999, 9.7%
n 2002 and 8% in 2003 [11]. This rate is consider-
bly less than the reported rates of >50% at other
nstitutions [7]. In the current study, pre-treatment
ultures and sensitivities were performed in 85%
f patients, baseline renal function in 98.6% and
he average treatment duration was approximately
days. Of the 15% of patients who did not have
retreatment cultures and sensitivities, 8% were
n the prophylaxis group. According to the estab-
ished guidelines, vancomycin use was considered
nappropriate for 26 (35%) patients. The major-
ty of inappropriate vancomycin utilization was
rescribed for empirical coverage (58%). Several
tudies in the past two decades evaluated the uti-
ization of vancomycin in hospitalized adult and
ediatric patients. In those studies, investigators
eported up to 65% inappropriate use of vancomycin
ased on institution speciﬁc criteria and/or CDC
ecommendations [13—18]. In a recent study from
razil utilizing the same guidelines showed that
ancomycin use was appropriate in 34.3% during
he ﬁrst 24 h and in 33.0% after 72 h [19]. In the
ost-intervention period, compliance with guide-
ines for empirical use of vancomycin improved
rom 21% in the pre-intervention phase to 85%
fter the intervention (P = .0001). In addition, com-
liance with vancomycin use in speciﬁc therapy
as 100% compared to 82%. This ﬁnding is con-
istent with a similar study where the compliance
ncreased from 47% to 73% with educational activity
20]. Thus, these ﬁndings suggest that the physi-
ians adherence to the guidelines improve with
imple education and a positive interaction of phar-
acist and physicians.
Of the 49 patients who had therapeutic van-omycin monitoring, 31% patients had both peak
nd trough (P&T) levels around the third dose. The
ther 69% patients had peak and/or trough lev-
ls taken at different times other than the third
ose. The correct timing for peak and trough blood145
evels was acceptable in 83% and 97% of patients,
espectively. However, it is important to note that
ancomycin peaks are not routinely monitored due
o lack of clinical signiﬁcance and correlation with
fﬁcacy. In a study from Iran, no therapeutic van-
omycin monitoring and no appropriate adjustment
f dosage with respect to serum levels were done
13].
Trough serum vancomycin concentrations are
he most accurate and practical method for mon-
toring vancomycin effectiveness and should be
btained just before the next dose at steady-
tate conditions [21]. Through continued education
f health care professionals, the compliance rate
ith trough level monitoring increased from 35% in
he pre-intervention period to 67.7% in the post-
ntervention period. Measuring steady-state trough
erum concentrations of vancomycin is helpful to
valuate the adequacy of vancomycin dosages [22].
In conclusion, in addition to the utilization of
DC based criteria for appropriate vancomycin
sage, we had shown that patient’s chart review
y a clinical pharmacists, physicians feedback when
uidelines were not met and educational efforts
re effective strategies to decrease inappropriate
ancomycin usage. Similarly, these simple interven-
ions were shown previously to be effective [20].
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